PT  - JOURNAL ARTICLE
AU  - Paul Emery
AU  - Anthony Sebba
AU  - Tom W J Huizinga
TI  - Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis
AID  - 10.1136/annrheumdis-2013-203485
DP  - 2013 Dec 01
TA  - Annals of the Rheumatic Diseases
PG  - 1897--1904
VI  - 72
IP  - 12
4099  - http://ard.bmj.com/content/72/12/1897.short
4100  - http://ard.bmj.com/content/72/12/1897.full
SO  - Ann Rheum Dis2013 Dec 01; 72
AB  - Clinical evidence demonstrates coadministration of tumour necrosis factor inhibitor (TNFi) agents and methotrexate (MTX) is more efficacious than administration of TNFi agents alone in patients with rheumatoid arthritis, leading to the perception that coadministration of MTX with all biologic agents or oral disease-modifying antirheumatic drugs is necessary for maximum efficacy. Real-life registry data reveal approximately one-third of patients taking biologic agents use them as monotherapy. Additionally, an analysis of healthcare claims data showed that when MTX was prescribed in conjunction with a biologic agent, as many as 58% of patients did not collect the MTX prescription. Given this discrepancy between perception and real life, we conducted a review of the peer-reviewed literature and rheumatology medical congress abstracts to determine whether data support biologic monotherapy as a treatment option for patients with rheumatoid arthritis. Our analysis suggests only for tocilizumab is there evidence that the efficacy of biologic monotherapy is comparable with combination therapy with MTX.